Eli Lilly and Co (XSWX:LLY) Other Operating Expense: CHF0 Mil (TTM As of Mar. 2026)


XSWX:LLY Eli Lilly and Co XSWX:LLY
100 GF Score
Price CHF970.00
GF Value CHF1,132.28
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Other Operating Expense?

Eli Lilly and Co XSWX:LLY 100 Other Operating Expense is CHF0 Mil as of Mar. 2026. GuruFocus rates XSWX:LLY with a GF Score™ of 100/100 and a GF Value™ of CHF1,132.28 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Eli Lilly and Co's Other Operating Expense for the three months ended in Mar. 2026 was CHF0 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was CHF0 Mil.

Eli Lilly and Co's quarterly Other Operating Expense increased from Sep. 2025 (CHF0 Mil) to Dec. 2025 (CHF0 Mil) and increased from Dec. 2025 (CHF0 Mil) to Mar. 2026 (CHF0 Mil).

Eli Lilly and Co's annual Other Operating Expense declined from Dec. 2023 (CHF0 Mil) to Dec. 2024 (CHF-0 Mil) but then increased from Dec. 2024 (CHF-0 Mil) to Dec. 2025 (CHF0 Mil).

Eli Lilly and Co Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Other Operating Expense Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 0.00
XSWX:LLY
100GF Score
Eli Lilly and Co XSWX:LLY
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of CHF0 Mil mean?
Eli Lilly and Co (XSWX:LLY) has a Other Operating Expense of CHF0 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Other Operating Expense too high?
Eli Lilly and Co's current Other Operating Expense is CHF0 Mil. Overall, Eli Lilly and Co has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Other Operating Expense compare to JNJ and ABBV?
Eli Lilly and Co's Other Operating Expense of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Other Operating Expense is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (XSWX:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF1,132.28, compared to a current price of CHF970.00 — trading 14.3% below its estimated fair value. The current Other Operating Expense is CHF0 Mil. Eli Lilly and Co's overall GF Score™ is 100/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Eli Lilly and Co (XSWX:LLY), the current Other Operating Expense is CHF0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (XSWX:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of CHF970.00 is trading 14.3% below its estimated GF Value™ of CHF1,132.28. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for XSWX:LLY:

  • Other Operating Expense: CHF0 Mil
  • GF Value™: CHF1,132.28 vs. price of CHF970.00 (14.3% below fair value)
  • GF Score™: 100/100 with 6 warning signs

No single metric tells the full story. See the XSWX:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
100GF Score

Get the complete analysis for XSWX:LLY

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF970.00
Price
CHF1,132.28
GF Value